TFEB
Introduction
[Tfeb](/entities/tfeb) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
<div class="infobox infobox-gene"> [@tfeb2020]
<table> [@tfeb2018]
<tr><th>Gene Symbol</th><td>TFEB</td></tr> [@tfebmediated2019]
<tr><th>Full Name</th><td>Transcription Factor EB</td></tr> [@small2021]
<tr><th>Chromosomal Location</th><td>6p21.1</td></tr> [@tfeb2017]
<tr><th>NCBI Gene ID</th><td><a href="https://www.ncbi.nlm.nih.gov/gene/7942" target="_blank">7942</a></td></tr>
<tr><th>OMIM</th><td><a href="https://www.omim.org/entry/609006" target="_blank">609006</a></td></tr>
<tr><th>Ensembl ID</th><td>ENSG00000147889</td></tr>
<tr><th>UniProt ID</th><td><a href="https://www.uniprot.org/uniprot/Q9UJX0" target="_blank">Q9UJX0</a></td></tr>
<tr><th>Associated Diseases</th><td>[Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), [Lysosomal Storage Disorders](/diseases/lysosomal-storage-disorders)</td></tr>
</table>
</div>
Overview
TFEB (Transcription Factor EB) is a member of the MITF/TFE family of transcription factors and serves as a master regulator of lysosomal biogenesis and [autophagy](/entities/autophagy). TFEB controls the cellular degradative capacity by coordinating the expression of genes involved in autophagy, lysosomal function, and lipid metabolism.
...TFEB
Introduction
[Tfeb](/entities/tfeb) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
<div class="infobox infobox-gene"> [@tfeb2020]
<table> [@tfeb2018]
<tr><th>Gene Symbol</th><td>TFEB</td></tr> [@tfebmediated2019]
<tr><th>Full Name</th><td>Transcription Factor EB</td></tr> [@small2021]
<tr><th>Chromosomal Location</th><td>6p21.1</td></tr> [@tfeb2017]
<tr><th>NCBI Gene ID</th><td><a href="https://www.ncbi.nlm.nih.gov/gene/7942" target="_blank">7942</a></td></tr>
<tr><th>OMIM</th><td><a href="https://www.omim.org/entry/609006" target="_blank">609006</a></td></tr>
<tr><th>Ensembl ID</th><td>ENSG00000147889</td></tr>
<tr><th>UniProt ID</th><td><a href="https://www.uniprot.org/uniprot/Q9UJX0" target="_blank">Q9UJX0</a></td></tr>
<tr><th>Associated Diseases</th><td>[Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), [Lysosomal Storage Disorders](/diseases/lysosomal-storage-disorders)</td></tr>
</table>
</div>
Overview
TFEB (Transcription Factor EB) is a member of the MITF/TFE family of transcription factors and serves as a master regulator of lysosomal biogenesis and [autophagy](/entities/autophagy). TFEB controls the cellular degradative capacity by coordinating the expression of genes involved in autophagy, lysosomal function, and lipid metabolism.
In the context of neurodegeneration, TFEB has emerged as a critical therapeutic target for Alzheimer's Disease, Parkinson's Disease, and lysosomal storage disorders. TFEB activity is regulated by mTORC1-mediated phosphorylation, which controls its subcellular localization and transcriptional activity. Dysregulation of TFEB contributes to impaired protein clearance and accumulation of toxic aggregates in neurodegenerative diseases.
Function
TFEB (Transcription Factor EB) is a master regulator of lysosomal biogenesis and autophagy. It belongs to the MITF/TFE family of basic helix-loop-helix leucine zipper transcription factors. TFEB controls the expression of genes involved in autophagy (including LC3, ATG proteins), lysosomal function (including cathepsins, LAMP proteins), and lipid metabolism[@tfeb2019].
TFEB activity is regulated by phosphorylation through mTORC1. Under nutrient-rich conditions, TFEB is phosphorylated and retained in the cytoplasm. Upon starvation or mTORC1 inhibition, TFEB translocates to the nucleus where it activates its target genes. This makes TFEB a key integrator of cellular energy status and autophagy[@tfeb2020].
Disease Associations
Alzheimer's Disease
TFEB activation promotes clearance of [amyloid-beta](/proteins/amyloid-beta) plaques through enhanced autophagy. In AD models, TFEB overexpression reduces amyloid burden and improves cognitive function. TFEB activity is impaired in AD brain, contributing to defective autophagy and protein aggregate accumulation. TFEB is considered a therapeutic target for AD[@tfeb2018].
Parkinson's Disease
TFEB-mediated autophagy is crucial for clearing [α-synuclein](/proteins/alpha-synuclein) aggregates in PD. TFEB activation enhances the clearance of toxic protein aggregates and protects dopaminergic [neurons](/entities/neurons). Impaired TFEB activity contributes to α-synuclein accumulation in PD models. TFEB activators are being explored as PD therapeutics[@tfebmediated2019].
Lysosomal Storage Disorders
TFEB is a key therapeutic target for lysosomal storage disorders (LSDs). TFEB overexpression or activation can enhance lysosomal biogenesis and partially compensate for deficient lysosomal enzyme activity. This approach has shown promise in models of Gaucher disease, Pompe disease, and other LSDs[@small2021].
Expression
TFEB is ubiquitously expressed with high expression in tissues with high lysosomal activity, including liver, kidney, and brain. In the brain, TFEB is expressed in neurons and glial cells. Under basal conditions, TFEB localizes to the cytoplasm; upon autophagy induction, it translocates to the nucleus. TFEB expression in neurons is particularly important for maintaining protein homeostasis through autophagy[@tfeb2017].
Key Publications
[TFEB as master regulator of lysosomal biogenesis (2019)](https://doi.org/10.1016/j.tcb.2019.04.004)
[TFEB and autophagy in neurodegeneration (2020)](https://doi.org/10.1016/j.neuropharm.2020.108057)
[TFEB activation reduces amyloid-beta in AD models (2018)](https://pubmed.ncbi.nlm.nih.gov/29429891/)
[TFEB-mediated clearance of alpha-synuclein in PD (2019)](https://pubmed.ncbi.nlm.nih.gov/31128641/)
[Small molecule TFEB activators for neurodegeneration (2021)](https://doi.org/10.1016/j.pharmthera.2021.107893)
[TFEB in lysosomal storage disease therapy (2017)](https://pubmed.ncbi.nlm.nih.gov/28347059/)Background
The study of Tfeb has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Cross-References
- [TFEB Protein](/proteins/tfeb-protein)
- [Autophagy](/mechanisms/autophagy)
- [Lysosomal Pathway](/mechanisms/lysosomal-degradation)
- [mTOR Signaling](/mechanisms/mtor-signaling-neurodegeneration)
See Also
- [TFEB Signaling in Neurodegeneration](/mechanisms/tfeb-signaling-neurodegeneration)
- [TFEB Protein](/proteins/tfeb-protein)
- [Autophagy Pathway](/mechanisms/autophagy)
- [Lysosomal Degradation](/mechanisms/lysosomal-degradation)
- [mTOR Signaling](/mechanisms/mtor-signaling-neurodegeneration)
- [Protein Homeostasis](/mechanisms/protein-homeostasis)
- [Genes Index](/genes)
External Links
- [NCBI Gene - TFEB](https://www.ncbi.nlm.nih.gov/gene/7942)
- [UniProt - TFEB](https://www.uniprot.org/uniprot/Q9UJX0)
- [Allen Brain Atlas - TFEB Expression](https://portal.brain-map.org/)
Pathway Diagram
The following diagram illustrates key molecular interactions and regulatory relationships for TFEB, derived from the SciDEX knowledge graph.
Mermaid diagram (expand to render)
References
[Unknown, TFEB as master regulator of lysosomal biogenesis (2019) (2019)](https://doi.org/10.1016/j.tcb.2019.04.004)
[Unknown, TFEB and autophagy in neurodegeneration (2020) (2020)](https://doi.org/10.1016/j.neuropharm.2020.108057)
[Unknown, TFEB activation reduces amyloid-beta in AD models (2018) (2018)](https://pubmed.ncbi.nlm.nih.gov/29429891/)
Unknown, TFEB-mediated clearance of alpha-synuclein in PD (2019) (2019)
[Unknown, Small molecule TFEB activators for neurodegeneration (2021) (2021)](https://doi.org/10.1016/j.pharmthera.2021.107893)
[Unknown, TFEB in lysosomal storage disease therapy (2017) (2017)](https://pubmed.ncbi.nlm.nih.gov/28347059/)From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
- [TFEB-PGC1α Mitochondrial-Lysosomal Decoupling](/hypothesis/h-e5a1c16b) — <span style="color:#ffd54f;font-weight:600">0.52</span> · Target: TFEB
- [The Mitochondrial-Lysosomal Metabolic Coupling Dysfunction](/hypothesis/h-e3e8407c) — <span style="color:#ffd54f;font-weight:600">0.52</span> · Target: TFEB
Pathway Diagram
The following diagram shows the key molecular relationships involving TFEB discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)